the present invention is related to a taxane composition that does not contain cremophor el or tween . the taxane composition in accordance with the present invention has a low toxicity and few side effects , further , the taxane composition in accordance with the present invention has a convenient way for its administration . the term “ taxanes ” used herein referred to , includes but is not limited to , paclitaxel , docetaxel or derivative of taxanes . in the present invention , a pharmaceutical composition containing taxanes comprising pharmaceutically acceptable excipients without tween . preferably , the pharmaceutical composition is an injection ; more preferably , the pharmaceutical composition in accordance with the present invention does not contain any water molecules . the pharmaceutical composition is dissolved in a solvent without containing water molecules , and can be administered without diluting beforehand . the pharmaceutical composition in accordance with the present invention is satisfactorily stable . the process for preparing the pharmaceutical composition in accordance with the present invention requires only the mixing well of the components . the process described in the present invention needs fewer steps than the conventional one . further , after emulsifying the pharmaceutical composition containing taxanes , the pharmaceutical composition becomes more stable . due to the pharmaceutical composition not containing tween , the cost and the side effects of the pharmaceutical composition of the present invention can be significantly reduced in relation to prior art . taxanes are only slightly soluble in water , but is well soluble in organic solutions including cremophor el , dimethylacetamide ( dma ), dimethylsulfoxide ( dmso ), ethanol , tween , polyethylene glycol ( peg ), propylene glycol ( pg ). however , taxanes will precipitate in the above solutions if they come into contact with water . even when solved in nonionic surfactants , taxanes also become precipitated when diluting with an injection after 4 to 8 hours . taxanes also can dissolve in oily solutions including oleic acid , safflower oils , corn oil , soybean oil . the process for preparing the pharmaceutical composition containing taxanes comprises dissolving taxanes in an organic solution and an emulsifying agent without water , then mixing with a co - surfactant , such as kollidon , puronic acid , lecithin or phospholipid . the pharmaceutical composition in accordance with the present invention is only mixed with an injection before use . preferably , the pharmaceutical composition is an injection . after 24 hours of injection , taxanes in the emulsifying agent are still stable , and no crystals form . the sizes of the emulsifying particles containing taxanes in the pharmaceutical composition neither change nor cause creaming , and the emulsifying particles can prevent light that would degrade or damage taxanes . the way to prepare the present invention is to only mix the components well by a conventional stirring apparatus and no complex apparatus is needed . due to the present pharmaceutical composition not containing any water molecules , the present pharmaceutical composition can be stored for long periods . according to the stability test described in the present invention , the pharmaceutical composition can be stored at a room temperature for more than two years . in the present invention , taxanes may be dissolved in a condensed emulsifying agent and can be diluted and then administered easily . the concentration of taxanes of the pharmaceutical composition may be 40 mg / ml , and can be diluted to 0 . 16 to 0 . 30 mg / ml for clinical injection . to administer the present pharmaceutical composition is the same as the conventional products such as taxotere ®, and has fewer side effects . this invention is illustrated further by the following non - limiting examples . all of the literature and publications recited in the context of the present disclosure are incorporated herein by reference . the components to prepare the present pharmaceutical composition are described in table 1 . the procedure for preparing the pharmaceutical composition is described as follows . the excipients including dspc , lutrol , kollidon , peg 200 and ethanol were mixed and then dissolved in a 40 ° c . water bath . when all the excipients had dissolved , taxanes were added into the above excipient liquid to obtain a mixture . the mixture was swung in a 40 ° c . water bath for 2 hours to obtain a condensed pharmaceutical composition containing taxanes . the pharmaceutical composition containing taxanes was stored at 25 ° c .± 2 ° c . and 40 ° c .± 2 ° c . for 6 months and no degradation was observed ( table 2 ). 2 . 5 ml of the condensed pharmaceutical composition was added to 500 ml 5 % dextrose ® and shaken for 1 minute to mix the pharmaceutical composition well for the stability test and the crystal forming test . a filter with 0 . 45 μm sieve was used for filtering the pharmaceutical composition and to test the crystal forming rate . the above test demonstrated that no crystal formed in 24 hours and the results are shown in table 3 . further , the emulsifying particles maintained sizes of 150 to 20 nm during the 24 - hour period . in fact , the sizes of the emulsifying particles do not significantly change after the pharmaceutical composition has been mixed with 5 % dextrose ®. the present example for preparing the pharmaceutical composition containing taxanes , and phospholipid in the excipient can be any kind of phospholipid such as centrophase 31 . the components of the pharmaceutical composition described in example 2 are listed in table 4 . the procedure for preparing the pharmaceutical composition is described as follows . the excipients including centrophase 31 and ethanol were mixed and then dissolved in a 40 ° c . water bath . when all the excipients had dissolved , taxanes were added into the above excipient liquid to obtain a mixture . the mixture was swung in a 40 ° c . water bath for 2 hours to obtain a condensed pharmaceutical composition containing taxanes . the pharmaceutical composition containing taxanes was stored at 25 ° c .± 2 ° c . and 40 ° c .± 2 ° c . for 6 months and no degradation was observed ( table 5 ). 5 ml of the condensed pharmaceutical composition was added to 500 ml 5 % dextrose ® and shaken for 1 minute to mix the pharmaceutical composition well for the stability test and the crystal forming test . a filter with 0 . 45 μm sieve was used for filtering the pharmaceutical preparation and to test the crystal forming rate . the above test demonstrated that no crystal formed within 24 hours and the results are shown in table 6 . further , the emulsifying particles maintained sizes of 150 to 20 nm during the 24 - hour period . the present example for preparing the pharmaceutical composition containing taxanes , and the pharmaceutical composition has excellent stability . the components of the pharmaceutical composition described in example 3 are listed in table 7 . the procedure for preparing the pharmaceutical composition is described as follows . the excipients including phospholipon 90g , and ethanol were mixed and then dissolved in a 40 ° c . water bath . when all the excipients had dissolved , taxanes were added into the above excipient liquid to obtain a mixture . the mixture was swung in a 40 ° c . water bath for 2 hours to obtain a condensed pharmaceutical composition containing taxanes . the pharmaceutical composition containing taxanes was stored at 25 ° c .± 2 ° c . and 40 ° c .± 2 ° c . for 6 months and no degradation was observed . ( table 8 ). 12 . 5 ml of the condensed pharmaceutical composition was added to 500 ml 5 % dextrose ® and shaken for 1 minute to mix the pharmaceutical composition well for the stability test and the crystal forming test . a filter with 0 . 45 μm sieve was used for filtering the pharmaceutical composition and to test the crystal forming rate . the above test demonstrated that no crystal formed within 24 hours and the results are shown in table 9 . further , the emulsifying particles maintained their sizes of 150 to 20 nm during the 24 - hour period . the present example for preparing the pharmaceutical composition containing taxanes , and the pharmaceutical composition with no enhancer ( hlb & gt ; 10 ) still had excellent stability . the components of the pharmaceutical composition described in example 4 are listed in table 10 . the procedure for preparing the pharmaceutical composition is described as follows . the excipients including phospholipon 90g , propylene glycol and ethanol were mixed and then dissolved in a 40 ° c . water bath . when all the excipients had dissolved , taxanes were added into the above excipient liquid to obtain a mixture . the mixture was swung in a 40 ° c . water bath to obtain a condensed pharmaceutical composition containing taxanes . the pharmaceutical composition containing taxanes was stored at 25 ° c .± 2 ° c . and 40 ° c .± 2 ° c . for 6 months and no degradation was observed ( table 11 ). 20 ml of the condensed pharmaceutical composition was added to into 500 ml 5 % dextrose ® and shaken 1 minute to mix the pharmaceutical composition well for the stability test and the crystal forming test . a filter with 0 . 45 μm sieve was used for filtering the pharmaceutical composition and to test the crystal forming rate . the above test demonstrated that no crystal formed within 24 hours and the results are shown in table 12 . the present example is for preparing the pharmaceutical composition containing taxanes with excellent stability . the components of the pharmaceutical composition described in example 5 are listed in table 13 . the procedure for preparing the pharmaceutical composition is described as follows . the excipients including phospholipon 90g and solutrol hs15 and docetaxel were mixed and dissolved in a water bath to obtain a condensed pharmaceutical composition containing taxanes . the pharmaceutical composition containing taxanes was stored at 25 ° c .± 2 ° c . and 40 ° c .± 2 ° c . for 6 months and no degradation was observed ( table 14 ). 3 . 75 ml of the condensed pharmaceutical composition was added to into 500 ml 5 % dextrose ® and shaken for 1 minute to mix the pharmaceutical composition well for the stability test and the crystal forming test . a filter with 0 . 45 μm sieve was used for filtering the pharmaceutical and to test the crystal forming rate . the above test demonstrated that no crystal formed within 24 hours and the results are shown in table 15 . further , the emulsifying particles maintained sizes of 150 to 20 nm during the 24 - hour period . even though numerous characteristics and advantages of the present invention have been set forth in the foregoing description , together with details of the structure and features of the invention , the disclosure is illustrative only . changes may be made in the details , especially in matters of shape , size , and arrangement of parts within the principles of the invention to the full extent indicated by the broad general meaning of the terms in which the appended claims are expressed .
pharmaceutical compositions containing taxanes having about 5 to about 75 % phospholipid , about 0 . 01 to about 50 % of a surfactant of an hlb value greater than 10 , about 0 . 01 to about 50 % alcohol and about 0 . 01 to about 40 % taxane or a derivative thereof .